Arsenic trioxide/idarubicin/tretinoin
- PDF / 169,189 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 55 Downloads / 202 Views
1 S
Severe infection: case report In a retrospectively study of 118 patients who received treatment for acute promyelocytic leukemia (APL) from January 2008 to December 2017, one patient [age and sex not stated] died because of infection during treatment with arsenic trioxide, idarubicin and tretinoin for APL. The patient, who had been diagnosed with APL, started receiving induction therapy with IV arsenic trioxide 0.16 mg/m2/day as 2-hour continuous infusion, oral tretinoin [all-trans-retinoic acid] 20 mg/m2/day in divided doses on days 1 to 28 and IV idarubicin 8 mg/m2/day on days 3, 5 and 7. During induction therapy, the patient died due to severe infection. Yang S, et al. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic 803500043 Leukemia. Clinical Lymphoma, Myeloma & Leukemia 20: e382-e391, No. 7, Jul 2020. Available from: URL: http://doi.org/10.1016/j.clml.2019.10.003
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
Data Loading...
